Legal status · United States
Is AT673 legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. AT673 is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 2 human studies are cited on its profile.
AT673 in the United States at a glance
| Classification | Investigational, not approved |
|---|---|
| Note | Phase 2 recruiting in combination with semaglutide. No approval anywhere and no published results. |
| FDA approval status | Investigational. Not approved anywhere. Phase 2 recruiting. |
| Human studies cited | 2 of 2 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the AT673 profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
AT673 is being studied in registered clinical trials but has not received FDA marketing approval in the United States.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What AT673 is
A GIP receptor antagonist being added to semaglutide in a phase 2 trial of 150 people. It is the exact mirror of NNC0480-0389, which adds a GIP agonist to the same drug.
If you want one fact that captures how unsettled incretin pharmacology is, it is this pair. Two companies are in phase 2 adding opposite interventions at the same receptor to the same background drug, for the same indication, at the same time.
Mechanism: An antagonist at the GIP receptor, intended to block rather than activate the receptor tirzepatide agonises, given alongside a GLP-1 receptor agonist. The mechanistic case comes from GIP receptor knockout mice being protected against diet-induced obesity, and from the observation that a naturally occurring truncated GIP fragment blocks its own receptor in humans.
Regulatory history: Investigational. Not approved anywhere. Phase 2 recruiting.
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for AT673 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
AT673 in other countries
Frequently asked questions
Is AT673 legal in the United States?
No. AT673 is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 2 human studies are cited on its profile. Note: Phase 2 recruiting in combination with semaglutide. No approval anywhere and no published results.
Can I buy AT673 in the United States?
No approved product exists to buy. In the United States AT673 is classified as "Investigational, not approved", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors. Note: Phase 2 recruiting in combination with semaglutide. No approval anywhere and no published results.
Is AT673 FDA approved?
No. FDA status: Investigational. Not approved anywhere. Phase 2 recruiting.. Current US classification: "Investigational, not approved". On the evidence, 2 human studies are cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for AT673 live on its compound profile.
AT673 profileThis page is general information about the regulatory status of AT673 in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.